The Atorvastatin Goal Achievement Across Risk Levels: (ATGOAL) Study in Thailand
Chaicharn Deerochanawong MD*, Peera Buranakitjaroen MD**, Wannee Nitiyanant MD**, Jithanorm Suwantamee MD***, Chumpol Piamsomboon MD***, Varaphon Vongthavaravat MD****, Nijasri Charnnarong Suwanwela MD****, Natapong Kosachunhanun MD*****, Apichard Sukonthasarn MD*****
Affiliation : * Rajavithi Hospital, ** Siriraj Hospital, ***Pramongkutklao Hospital, ****Chulalongkorn Memorial Hospital, *****Maharaj Nakorn Chiang Mai University
Objective : To evaluate the efficacy and safety of atorvastatin at the starting doses of 10, 20, 40 mg and evaluate
the effectiveness of 1 step titrate up regimen.
Materials and Methods : Two hundred and forty two subjects with dyslipidemia were enrolled and assigned the
appropriate dose in relation to their individual cardiovascular risk status and baseline LDL-C levels. If the
NCEP targets were not achieved, the doses were titrated up at week 4 and the primary efficacy was evaluated
at week 8.
Results : A majority of subjects (88.8%) achieved their LDL-C goals at week 8. Almost all of the subject’s LDL-
C levels reached their goals by week 2 and 4 (81.6% and 87.1%, respectively). Only 10.7% (n=25) required
the sole titration. Each dose provided significant decreases in LDL-C (average -46.4%). Only 36 subjects
experienced treatment related adverse events, the majority of these were in the high-risk group (n=22) with
only one subject registering a serious adverse event.
Conclusion : Atorvastatin is effective and safe for Thai patients with dyslipidemia. The appropriate starting
dose has contributed in the achievement of cholesterol reduction.
Keywords : Atorvastatin, Dyslipidemia, Treatment
